Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2007-07-18 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PIERRELATTE (26700), Drome
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE PARVEAU DESSEIGNE : revenue, balance sheet and financial ratios
PHARMACIE PARVEAU DESSEIGNE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PIERRELATTE (26700),
this company of category PME
shows in 2023 a revenue of 1.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE PARVEAU DESSEIGNE (SIREN 499135853)
Indicator
2023
2022
2021
2020
2019
2018
2017
Revenue
1 810 590 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
95 963 €
204 858 €
158 259 €
135 812 €
170 027 €
141 199 €
125 818 €
EBITDA
126 100 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
5.3%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2023, PHARMACIE PARVEAU DESSEIGNE achieves revenue of 1.8 M€. After deducting consumption (1.3 M€), gross margin stands at 505 k€, i.e. a rate of 28%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 126 k€, representing 7.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 96 k€, i.e. 5.3% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2023)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 810 590 €
Gross margin (2023)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
505 209 €
EBITDA (2023)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
126 100 €
EBIT (2023)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
124 955 €
Net income (2023)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
95 963 €
EBITDA margin (2023)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
7.0%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 91%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 48%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 6.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 5.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
Debt ratio (2023)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
91.096%
Financial autonomy (2023)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
47.569%
Cash flow / Revenue (2023)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
5.363%
Repayment capacity (2023)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
6.088
Asset age ratio (2023)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
Debt ratio
125.489
96.669
119.309
113.766
109.8
94.445
91.096
Financial autonomy
36.224
43.033
40.955
42.031
42.03
46.474
47.569
Repayment capacity
None
None
None
None
None
None
6.088
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
5.363%
Sector positioning
Debt ratio
91.12023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Average
In 2023, the debt ratio of PHARMACIE PARVEAU DESSEIGNE (91.10) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
47.57%2023
2021
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Average
In 2023, the financial autonomy of PHARMACIE PARVEAU DESSEIGNE (47.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
6.09 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE PARVEAU DESSEIGNE (6.09) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 366.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.6x. Financial charges are adequately covered by operations.
Liquidity ratio (2023)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
366.055
Interest coverage (2023)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
Liquidity ratio
201.701
269.034
317.507
316.965
305.666
382.678
366.055
Interest coverage
None
None
None
None
None
None
2.557
Sector positioning
Liquidity ratio
366.062023
2021
2022
2023
Q1: 135.25
Med: 189.78
Q3: 270.35
Excellent
In 2023, the liquidity ratio of PHARMACIE PARVEAU DESSEIGNE (366.06) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.56x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE PARVEAU DESSEIGNE (2.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 6 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. Favorable situation: supplier credit is longer than customer credit by 20 days. Inventory turnover is 39 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 51 days of revenue, i.e. 256 k€ to permanently finance.
Operating WCR (2023)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
255 710 €
Customer credit (2023)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
6 j
Supplier credit (2023)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
26 j
Inventory turnover (2023)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
39 j
WCR in days of revenue (2023)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
51 j
WCR and payment terms evolution PHARMACIE PARVEAU DESSEIGNE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
255 710 €
Inventory turnover (days)
0
0
0
0
0
0
39
Customer payment term (days)
0
0
0
0
0
0
6
Supplier payment term (days)
0
0
0
0
0
0
26
Positioning of PHARMACIE PARVEAU DESSEIGNE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 220 transactions of similar company sales
in 2023,
the value of PHARMACIE PARVEAU DESSEIGNE is estimated at
1 228 395 €
(range 783 496€ - 1 581 537€).
With an EBITDA of 126 100€, the sector multiple of 10.0x is applied.
The price/revenue ratio is 0.69x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2023
220 transactions
783k€1228k€1581k€
1 228 395 €Range: 783 496€ - 1 581 537€
NAF 5 année 2023
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
126 100 €×10.0x
Estimation1 255 441 €
753 141€ - 1 600 978€
Revenue Multiple30%
1 810 590 €×0.69x
Estimation1 247 375 €
897 345€ - 1 542 310€
Net Income Multiple20%
95 963 €×11.8x
Estimation1 132 313 €
688 614€ - 1 591 778€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE PARVEAU DESSEIGNE with other companies in the same sector:
Frequently asked questions about PHARMACIE PARVEAU DESSEIGNE
What is the revenue of PHARMACIE PARVEAU DESSEIGNE ?
The revenue of PHARMACIE PARVEAU DESSEIGNE in 2023 is 1.8 M€.
Is PHARMACIE PARVEAU DESSEIGNE profitable?
Yes, PHARMACIE PARVEAU DESSEIGNE generated a net profit of 96 k€ in 2023.
Where is the headquarters of PHARMACIE PARVEAU DESSEIGNE ?
The headquarters of PHARMACIE PARVEAU DESSEIGNE is located in PIERRELATTE (26700), in the department Drome.
Where to find the tax return of PHARMACIE PARVEAU DESSEIGNE ?
The tax return of PHARMACIE PARVEAU DESSEIGNE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE PARVEAU DESSEIGNE operate?
PHARMACIE PARVEAU DESSEIGNE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart